Centiva Capital LP Acquires New Stake in Natera, Inc. (NASDAQ:NTRA)

Centiva Capital LP acquired a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,641 shares of the medical research company's stock, valued at approximately $418,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Brevan Howard Capital Management LP increased its holdings in Natera by 859.3% during the 4th quarter. Brevan Howard Capital Management LP now owns 90,522 shares of the medical research company's stock valued at $14,330,000 after purchasing an additional 81,086 shares during the period. Bridgefront Capital LLC boosted its position in shares of Natera by 125.2% in the 4th quarter. Bridgefront Capital LLC now owns 4,628 shares of the medical research company's stock worth $733,000 after purchasing an additional 2,573 shares in the last quarter. Captrust Financial Advisors boosted its position in shares of Natera by 36.0% in the 4th quarter. Captrust Financial Advisors now owns 7,737 shares of the medical research company's stock worth $1,225,000 after purchasing an additional 2,048 shares in the last quarter. Bayesian Capital Management LP boosted its position in shares of Natera by 266.7% in the 4th quarter. Bayesian Capital Management LP now owns 38,500 shares of the medical research company's stock worth $6,095,000 after purchasing an additional 28,000 shares in the last quarter. Finally, Bellevue Group AG boosted its position in shares of Natera by 5.2% in the 4th quarter. Bellevue Group AG now owns 145,676 shares of the medical research company's stock worth $23,061,000 after purchasing an additional 7,217 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Insider Transactions at Natera

In other news, Director Gail Boxer Marcus sold 4,000 shares of Natera stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $151.61, for a total value of $606,440.00. Following the completion of the transaction, the director now owns 9,704 shares in the company, valued at approximately $1,471,223.44. The trade was a 29.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 2,562 shares of Natera stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $138.41, for a total value of $354,606.42. Following the completion of the transaction, the chief financial officer now owns 75,557 shares of the company's stock, valued at approximately $10,457,844.37. This trade represents a 3.28% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 152,436 shares of company stock worth $22,019,079. 7.60% of the stock is currently owned by company insiders.

Natera Price Performance

Shares of NTRA stock traded up $3.18 during trading hours on Friday, hitting $152.58. The stock had a trading volume of 307,596 shares, compared to its average volume of 1,382,896. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The stock has a market capitalization of $20.63 billion, a price-to-earnings ratio of -86.52 and a beta of 1.79. Natera, Inc. has a one year low of $92.14 and a one year high of $183.00. The stock's 50-day moving average price is $148.46 and its two-hundred day moving average price is $156.31.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm's revenue for the quarter was up 36.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.56) EPS. Equities analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on NTRA shares. The Goldman Sachs Group upped their price objective on Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Morgan Stanley upped their price objective on Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Royal Bank of Canada started coverage on shares of Natera in a research note on Thursday, March 13th. They set an "outperform" rating and a $251.00 target price for the company. UBS Group boosted their target price on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $180.00 target price on shares of Natera in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat, Natera has an average rating of "Moderate Buy" and a consensus price target of $182.12.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.